Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost

Abstract Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic’s evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate’s contemporary performance. For 985 recipients of an mRNA...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Nature Communications
Главные авторы: Bo Zhang, Youyi Fong, Lauren Dang, Jonathan Fintzi, Shiyu Chen, Jing Wang, Nadine G. Rouphael, Angela R. Branche, David J. Diemert, Ann R. Falsey, Daniel S. Graciaa, Lindsey R. Baden, Sharon E. Frey, Jennifer A. Whitaker, Susan J. Little, Satoshi Kamidani, Emmanuel B. Walter, Richard M. Novak, Richard Rupp, Lisa A. Jackson, Chenchen Yu, Craig A. Magaret, Cindy Molitor, Bhavesh Borate, Sydney Busch, David Benkeser, Antonia Netzl, Derek J. Smith, Tara M. Babu, Angelica C. Kottkamp, Anne F. Luetkemeyer, Lilly C. Immergluck, Rachel M. Presti, Martín Bäcker, Patricia L. Winokur, Siham M. Mahgoub, Paul A. Goepfert, Dahlene N. Fusco, Robert L. Atmar, Christine M. Posavad, Jinjian Mu, Mat Makowski, Mamodikoe K. Makhene, Seema U. Nayak, Paul C. Roberts, Peter B. Gilbert, Dean Follmann, Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team
Формат: Статья
Опубликовано: Nature Portfolio 2025-01-01
Online-ссылка:https://doi.org/10.1038/s41467-025-55931-w
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Internet

https://doi.org/10.1038/s41467-025-55931-w

Схожие документы